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Summary: This review of challenging diagnostic issues concerning high-grade endometrial
carcinomas is derived from the authors’ review of the literature followed by discussions at the
Endometrial Cancer Workshop sponsored by the International Society of Gynecological
Pathologists in 2016. Recommendations presented are evidence-based, insofar as this is
possible, given that the levels of evidence are weak or moderate due to small sample sizes and
nonuniform diagnostic criteria used in many studies. High-grade endometrioid carcinomas
include FIGO grade 3 endometrioid carcinomas, serous carcinomas, clear cell carcinomas,
undifferentiated carcinomas, and carcinosarcomas. FIGO grade 3 endometrioid carcinoma
is diagnosed when an endometrioid carcinoma exhibits > 50% solid architecture (excluding
squamous areas), or when an architecturally FIGO grade 2 endometrioid carcinoma exhibits
marked cytologic atypia, provided that a glandular variant of serous carcinoma has been
excluded. The most useful immunohistochemical studies to make the distinction between
these 2 histotypes are p53, p16, DNA mismatch repair proteins, PTEN, and ARID1A.
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Endometrial clear cell carcinomas must display prototypical architectural and cytologic
features for diagnosis. Immunohistochemical stains, including, Napsin A and p504s can be
used as ancillary diagnostic tools; p53 expression is aberrant in a minority of clear cell
carcinomas. Of note, clear cells are found in all types of high-grade endometrial carcinomas,
leading to a tendency to overdiagnose clear cell carcinoma. Undifferentiated carcinoma
(which when associated with a component of low-grade endometrioid carcinoma is termed
“dedifferentiated carcinoma”) is composed of sheets of monotonous, typically dyscohesive
cells, which can have a rhabdoid appearance; they often exhibit limited expression of
cytokeratins and epithelial membrane antigen, are usually negative for PAX8 and hormone
receptors, lack membranous e-cadherin and commonly demonstrate loss of expression
of DNA mismatch repair proteins and SWI-SNF chromatin remodeling proteins.
Carcinosarcomas must show unequivocal morphologic evidence of malignant epithelial
and mesenchymal differentiation. Key Words: Carcinosarcoma—Clear cell carcinoma—
Dedifferentiated carcinoma—Endometrioid carcinoma—Endometrium—FIGO Grade 3—
High grade—Serous carcinoma—Undifferentiated carcinoma.
High-grade endometrial cancers include FIGO grade 3
endometrioid carcinomas, serous carcinomas, clear cell
carcinomas, undifferentiated/dedifferentiated carcinomas,
and carcinosarcomas. Typical examples of these histo-
types are not difﬁcult to diagnose based on careful
examination of their morphologic features, allied with
conﬁrmatory immunohistochemistry if required. In some
cases, the histopathologic and immunohistochemical
characteristics are less clear-cut and overlap signiﬁcantly,
which makes accurate classiﬁcation difﬁcult. Even among
specialist gynecologic pathologists, the interobserver
reproducibility in the typing of high-grade endometrial
carcinomas is suboptimal, with reported kappa values
ranging between 0.55 and 0.68 (1–5).
Some studies have shown prognostic differences
between the histologic subtypes of high-grade endometrial
cancers. In an analysis of 4180 cases by the Surveillance,
Epidemiology, and End Results (SEER) Program, poorer
outcomes were observed in patients with serous carcinoma
and clear cell carcinoma compared with those with grade
3 endometrioid carcinoma (6,7). Other studies found that
patients diagnosed with serous carcinoma had poorer
survival than those with grade 3 endometrioid carcinoma
(8,9). In contrast, 3 studies of high-grade endometrial
carcinoma identiﬁed no signiﬁcant differences in survival
among patients with grade 3 endometrioid carcinoma,
serous carcinoma, and clear cell carcinoma (10–12).
Therefore, the issue of whether or not grade 3
endometrioid carcinoma is as clinically aggressive as
serous carcinoma and clear cell carcinoma has not been
conclusively settled. Much of this controversy is likely due
to the suboptimal interobserver reproducibility among
pathologists in the histotyping of high-grade endometrial
carcinomas.
In this review, we present an overview of the
histologic and immunohistochemical features of the
different subtypes of high-grade endometrial carcino-
mas, including a discussion of the challenges in
diagnosis and differential diagnosis. We present recom-
mendations based on the available literature to assist
pathologists in diagnosing these tumors.
FIGO GRADE 3 ENDOMETRIOID CARCINOMA
Definition
An endometrioid carcinoma with > 50% solid
architecture, or 6% to 50% solid architecture and
diffuse marked nuclear atypia. The presence of oval or
round glands, lined by columnar or cuboidal cells with
low-grade oval or round nuclei which are typically
pseudostratiﬁed, establishes endometrioid lineage. Squ-
amous metaplasia (morular or nonmorular) is common
and should not be included in the estimation of extent
of solid architecture when grading these tumors.
Key Morphologic Features
Grade 3 endometrioid carcinomas frequently arise
in association with endometrial hyperplasia. They are
predominantly solid (Fig. 1A), but gland formation is
usually seen at least focally (Fig. 1B), with evident
transition from one component to the other. The solid
component consists of large nests and occasional
trabeculae. The cells in the solid component resemble
those lining the glandular spaces. Nuclei usually have
moderate (grade 2) atypia, and mucinous or
squamous metaplasia is sometimes seen (13).
ENDOMETRIAL SEROUS CARCINOMA
Definition
An endometrial carcinoma that usually shows
marked and diffuse cytologic atypia and a papillary,
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FIG. 1. FIGO grade 3 endometrioid carcinoma. Solid architecture (A), glandular architecture with high nuclear grade (B).
FIG. 2. Serous carcinoma. Typical papillary and micropapillary architecture (A), glandular serous carcinoma recognized by highly atypical
nuclei and high nuclear:cytoplasmic ratios (B), intraepithelial serous carcinoma involving atrophic endometrial polyp (C).
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glandular or solid architecture (Figs. 2A, B). Features
deﬁnitional for endometrioid carcinoma and clear cell
carcinoma (see below) are lacking. Nearly every case
harbors a TP53 mutation (14), which is associated with
aberrant immunohistochemical expression of p53.
Key Morphologic Features
Serous carcinoma generally develops in the back-
ground of atrophic endometrium, sometimes in a
polyp (Fig. 2C). Most serous carcinomas show at least
focal areas of papillary growth, sometimes with
ﬁbrovascular stalks (Fig. 2A); however, this ﬁnding
may be absent. Budding and exfoliation of tumor
cells are typically seen. The tumors may also exhibit
irregular glands, often with slit-like spaces, but
sometimes with round spaces, or a solid growth
pattern (Fig. 2B). Psammoma bodies are found in
one-third of cases. Nuclei are hyperchromatic, contain
macronucleoli, are markedly atypical (grade 3), and
pleomorphic/bizarre forms are often present. Numerous
mitotic ﬁgures are usually found. Cytoplasm is often
scant, but may be more abundant, with a clear or
eosinophilic appearance (13,15,16). Some tumors lack
marked cytologic atypia, but the tumor cells show
hyperchromatic nuclei, increased nuclear:cytoplasmic
ratios, numerous apoptotic bodies and frequent
mitoses.
Distinction of FIGO Grade 3 Endometrioid Carcinoma
and Serous Carcinoma
Morphology
Recognition of key morphologic features detailed
above will permit this distinction in most cases.
Although serous carcinomas generally show greater
degrees of nuclear atypia and polymorphism than
grade 3 endometrioid carcinomas, they may both
exhibit high-grade atypia and solid growth patterns,
and serous carcinomas may show a predominantly
glandular growth pattern (13,15,16). Grade 3 endo-
metrioid carcinoma is typically predominantly solid,
but glandular or less commonly papillary formation is
seen at least focally, with transition from one
component to the other (13).
While the aforementioned features aid in distinguish-
ing endometrioid carcinomas and serous carcinomas in
many cases, there are some tumors that cannot be
reproducibly classiﬁed (Fig. 3). In a study of 56 tumors
diagnosed as high-grade endometrial carcinomas, 3
experienced gynecologic pathologists agreed on
histotype in only 62.5% of cases, and there was
disagreement with respect to the diagnosis of grade 3
endometrioid carcinoma versus serous carcinoma in 6
of 20 discrepant cases (2). In view of this difﬁculty,
ancillary methods, such as immunohistochemistry and
molecular testing, may be applied to aid classiﬁcation.
Immunohistochemistry
When evaluating immunomarker studies, it is
important to bear in mind that reported studies vary
in the cut-off points used to assess positive and
negative staining, making it difﬁcult to compare the
results of different studies.
In a study of 40 grade 3 endometrioid carcinomas
and 24 serous carcinomas (17), estrogen receptor
(ER), progesterone receptor (PR), p16, monoclonal
carcinoembryonic antigen, and vimentin were ex-
pressed in 50% versus 54%, 42% versus 54%, 25%
versus 92%, 3% versus 13%, and 81% versus 83% of
tumors, respectively. This suggests limited discrim-
inatory use for these markers; however, any degree of
staining was scored as positive, probably masking the
value of diffuse p16 expression in diagnosing serous
carcinoma. That the extent of p16 expression might be
important was illustrated by a study which found that
serous carcinoma showed p16 expression in 90% to
100% of cells, compared with 10% to 90% of cells in
grade 3 endometrioid carcinoma (18). Another study
(2) using a panel of ER, PR, p16, p53, and PTEN
found that the majority of serous carcinomas are
negative for ER and PR, positive for PTEN, diffusely
positive for p16 and exhibit aberrant mutation-type
FIG. 3. Diagnostically difficult endometrial carcinoma. This tumor
presented in a 45-yr-old woman with atypical endometrial hyper-
plasia. Sequencing revealed a POLE mutation, but no TP53
mutation. The final diagnosis was high-grade endometrioid
carcinoma; the presence of a POLE mutation is prognostically
favorable.
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expression (diffusely and strongly positive or entirely
negative) with p53, whereas grade 3 endometrioid
carcinomas are more likely to be positive for ER and
PR, negative for PTEN (correlating with genetic
aberrations of PTEN(19)), focally positive for p16 and
show wild-type staining for p53. However, exceptions
to this typical staining pattern occur in both tumor
types and in general a panel of markers is the most
reliable approach (2).
The insulin-like growth factor II mRNA-binding
protein family (IMP; IGFBP) consists of 3 proteins
(IMP1, IMP2, and IMP3). IMP2 is expressed in
virtually all serous carcinomas and grade 3 endome-
trioid carcinomas, but in one study, the former
showed staining in > 95% of tumor cells compared
with ≤ 75% of tumor cells in the latter (20). IMP3 has
been shown to be expressed in a majority (> 90%) of
serous carcinomas (21,22). A panel consisting of
IMP3, PTEN, p53, and beta-catenin was applied to
103 endometrial cancers (including 31 serous carcino-
mas and 16 grade 3 endometrioid carcinomas). IMP3,
PTEN, p53, and beta-catenin were detected in 17%
versus 100%, 28% versus 90%, 56% versus 84%, and
28% versus 0% of grade 3 endometrioid carcinomas
versus serous carcinomas, respectively (23). Another
immunohistochemical analysis of 180 endometrial
carcinomas including 34 grade 3 endometrioid carci-
nomas and 15 serous carcinomas (8) found that IMP3,
ER, PR, PTEN, p53, and p16 were detected in 20%,
82%, 68%, 61%, 39%, and 19% of grade 3 endome-
trioid carcinomas and 63%, 50%, 46%, 100%, 69%,
and 90% of serous carcinomas, respectively.
ARID1A is a tumor suppressor gene mutated in
∼50% of ovarian endometrioid and clear cell carci-
nomas, as well as a signiﬁcant percentage of the
corresponding uterine tumors, resulting in loss of
immunoexpression of its protein product, BAF250a.
Analysis of 190 high-grade endometrial cancers (24)
showed loss of BAF250a expression in 46% of grade 3
endometrioid carcinomas compared with 9% of serous
carcinomas. Aberrant p53 expression was found in
18% of grade 3 endometrioid carcinoma compared
with 78% of serous carcinomas. In addition, loss of
DNA mismatch repair (MMR) protein expression
(MLH1, PMS2, MSH2, MSH6) was observed in 57%
of grade 3 endometrioid carcinomas compared with
10% of serous carcinomas (24). These patterns of p53
and MMR protein expression have also been reported
in other studies (25).
The expression of high-mobility group AT-hook 2
(HMGA2) was compared in 68 grade 3 endometrioid
carcinomas and 71 serous carcinomas using tissue
microarrays. Staining of any extent was present in
61% of serous carcinomas versus 25% of grade 3
endometrioid carcinomas. When present, staining was
more diffuse in serous carcinoma. Serous endometrial
intraepithelial carcinomas were also HMGA2-positive
(26). In whole tissue sections, 91% of serous carcino-
mas were positive, usually with diffuse staining. All 5
cases of serous endometrial intraepithelial carcinoma
were positive, as were 37% of endometrioid carcino-
mas, usually with focal staining (26).
WT1 expression is usually focally positive (in up to
30% of cases) or negative in uterine serous carcinoma
(27), and this marker is therefore not routinely applied
in the differential diagnosis between grade 3 endome-
trioid carcinoma and serous carcinoma at this
anatomic site. However, since endometrioid carcino-
mas are usually WT1-negative, diffuse WT1 expres-
sion when present suggests a diagnosis of serous
carcinoma, including derivation from an adnexal
serous carcinoma.
In the most comprehensive study of potential
markers useful in the distinction between grade 3
endometrioid carcinoma and serous carcinoma pub-
lished to date, Han et al. (3) analyzed the diagnostic
role of 12 proteins (ER, PR, p16, p53, Ki-67, PTEN,
beta-catenin, vimentin, IMP3, TFF3, ARID1A, and
HNF1B) in this differential diagnosis. TFF3 expres-
sion, ARID1A loss and beta-catenin expression had
100% speciﬁcity in diagnosing grade 3 endometrioid
carcinoma, but relatively low sensitivity at 37%, 33%,
and 7%, respectively. p53, p16, and IMP3 stained
94%, 80% and 63% of serous carcinomas, respectively,
compared with 26%, 11%, and 11% of grade 3
endometrioid carcinomas (3).
In summary, although individual immunomarkers
are differentially expressed in these tumors, no single
marker is absolutely diagnostic of either grade 3
endometrioid carcinoma or serous carcinoma. Reach-
ing an accurate, reproducible diagnosis appears to be
feasible in most cases using a combination of careful
morphologic assessment supplemented by the judi-
cious use of immunohistochemistry with a panel of
stains rather than a single marker (Box 1). In general,
immunohistochemical markers that can be scored as
“all-or-none” or at least as diffuse versus nondiffuse
are likely to be assessed in a more reproducible
manner than those that require estimation of the
extent of staining or staining intensity. The former
group includes p16, p53 (Figs. 4A–C), PTEN, DNA
MMR proteins (Fig. 4D), and ARID1A (Fig. 4E).
ER, despite its expression in a signiﬁcant number of
serous carcinomas, appears to be useful in
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combination with these markers, while the evidence
for PR is less conclusive. The combination of ER, PR,
p16, p53, vimentin, PTEN, and IMP3 was 100%
concordant with morphology in the largest study to
address this differential diagnosis, with the
combination of ER, p16, and p53 being interpreted
as the most informative when applying a limited panel
of 3 markers (3); however, the role of IMP3 in
diagnosing serous carcinoma is more difﬁcult to assess
given the different cut-offs applied in different studies.
The presence of TFF3 staining, beta-catenin expression
and loss of MMR protein expression appears useful in
diagnosing grade 3 endometrioid carcinoma and these
markers may be included in extended panels.
The role of HMGA2 in this differential diagnosis
requires further research. Insufﬁcient evidence is
available to support the use of vimentin, Ki-67,
HNF1B, WT1 and IMP2, and monoclonal carci-
noembryonic antigen may be safely omitted from the
antibody panel. Molecular classiﬁcation of endome-
trial carcinomas has been shown to be superior to
immunohistochemistry as an ancillary technique (29),
but whether, and to what extent, it will replace
immunohistochemistry remains to be seen, especially
since it is more expensive, more time-consuming and
not available in many pathology laboratories.
CLEAR CELL CARCINOMA
Definition
An endometrial carcinoma demonstrating a combi-
nation of papillary (small round papillae lacking overt
stratiﬁcation; Fig. 5A), tubulocystic (Fig. 5B) and/or
solid (Fig. 5C) architectural patterns, with cuboidal or
polygonal cells containing nuclei with a variable
degree of pleomorphism (although usually lacking
overt pleomorphism). Hobnail tumor cells and
cytoplasmic clearing are often present but are not
required for diagnosis.
Key Morphologic Features
Clear cell carcinomas of the endometrium are
uncommon neoplasms that are likely to be over-
diagnosed. Accuracy in the diagnosis of clear cell
carcinoma is best achieved by strict adherence to
morphologic criteria that are essentially based on the
prototypical proﬁle of analogous tumors of the ovary,
where clear cell carcinomas are more common and are
more reproducibly diagnosed (30–32). The validity of
such an extrapolation is supported by the fact that
ovarian and endometrial clear cell carcinomas have
been shown to have highly similar gene expression,
proteomic, morphologic, and immunohistochemical
proﬁles (33–37).
Architectural Patterns
Clear cell carcinoma should display at least one of 3
architectural patterns: solid, papillary, and/or tubulo-
cystic. More than 80% of cases show an admixture of
2 or more patterns (34,38). The tubulocystic pattern
BOX 1. Distinction of FIGO Grade 3 Endometrioid
Carcinoma and Serous Carcinoma
Summary and recommendations:
 Carcinomas with a readily identiﬁable endometrioid
component, as evidenced by endometrioid type glands with
tall columnar epithelium and stratiﬁed nuclei, squamous or
mucinous differentiation, and with > 50% solid architecture
should be diagnosed as grade 3 endometrioid carcinoma.
 Carcinomas with a solid architecture and a glandular
component with serous differentiation (glands with papillae,
cellular tufts, high-grade nuclei with macronucleoli, and
atypical mitoses) should be diagnosed as serous carcinoma.
 Immunohistochemistry can be a useful adjunct for the
distinction between grade 3 endometrioid carcinoma and
serous carcinoma. This should be performed in conjunction
with careful histologic evaluation, as different subtypes may
have signiﬁcantly overlapping immunohistochemical proﬁles.
J A basic panel includes at least p53 and p16 with either ER
or PTEN.
J Double negative [p16-negative (nonblock type)/PTEN-
negative* and/or ARID1A-negative or p16-negative/
p53-wild-type] tumors are most likely endometrioid.
J Double positive tumors (p53 aberrant/mutation-type† and
diffuse strong p16 positive‡) that are also ER-negative§ are
more likely serous.
J Tumors with indeterminate histology and/or discordant
immunohistochemistry may be subjected to an expanded
immunohistochemical panel that includes DNA MMR
proteins (MLH1, PMS2, MSH2, MSH6), beta-catenin,
IMP3, and HMGA2.
J Loss of at least 1 DNA MMR protein‖ by
immunohistochemistry may be used to support the
diagnosis of endometrioid carcinoma.
*PTEN loss= 0% staining; †p53-aberrant/mutation-
type= strong staining in > 80% tumor cells or absent staining;
‡p16 is positive if > 90% strong staining; §ER positive
if > 50% staining; ‖DNA MMR protein loss is 0% staining.
Controls should be appropriate.
Unresolved questions:
 Is there a role for labeling tumors as indeterminate or
ambiguous if histology and immunohistochemistry are
insufﬁciently discriminatory?
 Should molecular genotyping be recommended to distinguish
grade 3 endometrioid carcinoma from serous carcinoma or to
avoid an indeterminate/ambiguous diagnosis?
 Do the immunohistochemical panels above routinely separate
genomically deﬁned variants of grade 3 endometrioid
carcinoma, such as those with POLE exonuclease domain
hotspot mutations or high copy number alterations?(28)
 How well do these immunomarkers perform in routine clinical
practice, given the paucity of rigorous external proﬁciency
testing programs that assess test characteristics?
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FIG. 4. Immunohistochemistry useful in distinction of serous carcinoma and high-grade endometrioid carcinoma. (A) p53 overexpression
(aberrant) may be seen in high-grade endometrioid carcinoma and serous carcinoma. (B) Null p53 phenotype (aberrant) may be seen in high-
grade endometrioid carcinoma and serous carcinoma. Note positive internal control. (C) Wild-type p53 expression, not seen in serous
carcinoma. (D) Loss of MLH1 expression (aberrant), not seen in serous carcinoma. (E) Geographic loss of ARID1A expression (left), not seen
in most serous carcinomas.
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is the most commonly encountered, and is at least
focally present in most cases (4,34,38), but the
papillary pattern is most frequently (28%–41%)
predominant (34,38–41).
Papillary pattern (Fig. 5A). The papillae of clear cell
carcinoma are most commonly in the form of small
rounded papillae. Stromal hyalinization is present in
the majority of tumors but typically involves only a
proportion of the papillae (34). Other papillary
patterns include architecturally complex papillae
with hierarchical branching, micropapillae, long and
slender papillae, or other nonspeciﬁc papillary
formations (34,40). The papillae of clear cell
carcinoma are lined by hobnail, cuboidal, or
polygonal cells with clear or eosinophilic cytoplasm,
and should not show extensive nuclear stratiﬁcation,
cellular tufting, or detached cellular budding.
Tubulocystic pattern (Fig. 5B). The tubulocystic
pattern represents a morphologic spectrum from glands/
tubules to cystic formations (34,38–43). At the tubular/
glandular end of this spectrum, the glands are relatively
uniform and display rounded contours with open lumina.
They may be extensively conﬂuent and “back-to-back” or
show an abundance of interglandular stroma. Increasing
cystic dilatation of the glands is usually accompanied by
less conﬂuence, although fully cystic units may also be
entirely conﬂuent. Tubular glands are lined by polygonal,
low cuboidal cells with clear to eosinophilic cytoplasm or
by hobnail cells. Cystic glands may be lined by similar
cells or by a bland, ﬂat cellular population. The
interglandular stroma may be hyalinized, myxoid,
inﬂamed, edematous, or ﬁbroblastic. Extensive nuclear
stratiﬁcation, cellular tufting, or detached cellular budding
should not be seen.
FIG. 5. Clear cell carcinoma. Papillary architecture (A), tubulocystic architecture (B), solid architecture (C).
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Solid pattern (Fig. 5C). The solid pattern is almost
invariably admixed with other patterns and is
characterized by diffuse sheets of polygonal cells
with well-deﬁned cell borders, with interspersed thin
ﬁbrous septa (34,38–43). Clear cells usually
predominate in the solid areas, although a
conspicuous population of oxyphilic cells is not
infrequent (34).
Cytologic Features
Cell types and stratiﬁcation. The cell types that may
be seen in clear cell carcinoma include polygonal cells
with clear or eosinophilic cytoplasm and well-deﬁned
cell membranes, hobnail cells, and attenuated hobnail
cells (ﬂat cells) (34,41). Nuclear stratiﬁcation in the
epithelium lining glands and papillae may be focally
present and is usually not prominent (34). Cellular
tufting or detached cellular budding should not be
diffusely present in clear cell carcinoma (34), and
squamous differentiation should be absent.
Atypia. A given case may display wide variation in
the degree of cytologic atypia but many cases show a
background of relative monomorphism, with scat-
tered or clustered cells exhibiting larger, pleomorphic
nuclei (34). Diffuse severe nuclear atypia is not
characteristic of clear cell carcinoma.
Mitotic index. The mitotic index may be quite
variable between tumors and even within the same
tumor, but overall, it is generally low (4,34,41). In
one study of 21 cases (41), 52% had 0 to 1 mitotic
ﬁgures per 10 high power ﬁelds, 29% showed 2 to 5
mitotic ﬁgures per 10 high-power ﬁelds and 19% had
≥ 6 mitotic ﬁgures per 10 high-power ﬁelds. Putative
cases of clear cell carcinoma exhibiting very high
levels of mitotic activity, especially when accom-
panied by severe atypia, warrant careful examina-
tion for other characteristic features of clear cell
carcinoma.
Immunohistochemical Features
The diagnosis of clear cell carcinoma should
primarily be based on its distinctive morphologic
features described above. However, immunohisto-
chemistry can be useful in some speciﬁc scenarios:
(1) ascertaining whether focal areas of clear cells in an
endometrial carcinoma represent true clear cell
carcinoma; and (2) evaluation of a tumor which
shows some morphologic features that are suggestive
but not diagnostic of clear cell carcinoma in a limited
sample (eg, biopsy or curettage).
The typical immunohistochemical proﬁle of clear
cell carcinoma is HNF1B-positive (Fig. 6A), Napsin
A-positive (Fig. 6B), ER-negative and PR-negative and
p53-wild-type (3,4,17,44–55). This immunohistochemical
panel is more useful in the distinction of clear cell
carcinoma from endometrioid carcinoma than from
serous carcinoma. The extent of expression of Napsin A
and HNF1B in serous carcinomas and endometrioid
carcinomas is signiﬁcantly lower than that in clear cell
carcinomas. HNF1B has high sensitivity for endometrial
clear cell carcinoma, but its speciﬁcity is lower than in
ovarian clear cell carcinoma. Moreover, there are
different antibodies against HNF1B, which vary in
quality. Use of monoclonal Napsin A is recommended,
as the polyclonal antibody lacks speciﬁcity (56). A small
percentage of prototypical endometrial clear cell
carcinomas are ER-positive, and clear cell change in
endometrioid carcinoma may be accompanied by
signiﬁcant diminution of ER and PR expression (52);
therefore ER and PR should always be used in
conjunction with a panel of other markers (57).
Aberrant mutation-type p53 immunohistochemical
expression is seen in up to one third of otherwise
typical clear cell carcinomas (44,47,58,59) (Fig. 6C)
and these cases are morphologically indistinguishable
from p53-wild-type cases (47,58). Nevertheless, p53
immunohistochemistry can still provide useful
information, as wild-type p53 staining minimizes the
probability that the tumor is a true serous carcinoma
(5), and mutation-type p53 expression is an adverse
prognostic factor in histotypically ambiguous tumors
(60). There is some evidence that p53-aberrant clear
cell carcinomas show a more aggressive, “serous-
like,” peritoneal pattern of spread (58,59). At the
molecular level, ∼14% of morphologically and
immunophenotypically characteristic clear cell
carcinomas display a proﬁle of mutations (mutations
in TP53 and PPP2R1A; wild-type PTEN, CTNNB1,
and ARID1A) typically seen in serous carcinoma
(47,48). These ﬁndings suggest that a subset of tumors
diagnosed as clear cell carcinomas might represent
manifestations of extreme morphologic mimicry by
serous carcinomas (48,61).
The serous carcinoma-associated markers p16 and
IMP3 may be expressed in clear cell carcinoma, and
are not particularly useful in the distinction between
these 2 tumor types (17,18,21,22,62,63). Although
IMP2 and HMGA2 are frequently expressed in serous
carcinomas (20,26), there are insufﬁcient data about
their expression in clear cell carcinoma. Similarly, the
diagnostic value of AMACR (α-methylacyl-coen-
zyme-A racemase or p504s), which has been reported
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to be frequently positive in clear cell carcinoma,
requires further study (64,65). Although loss of DNA
MMR protein expression is not useful in the
distinction of clear cell carcinoma and endometrioid
carcinoma, this ﬁnding would favor clear cell
carcinoma over serous carcinoma (24,44,66). In 2
recent studies, MMR deﬁciency was observed in 19%
of clear cell carcinomas (67) and 0% of serous
carcinomas (68).
Differential Diagnosis of Clear Cell Carcinoma
Prototypical examples of endometrial clear cell
carcinoma are characterized by a distinctive set of
histopathologic features (described above) that en-
ables their distinction from other histotypes
(6,7,10,11,34,38–43,69–100). The signiﬁcant interob-
server variation that has historically been associated
with the diagnosis of endometrial clear cell carcinoma
is in large part related to the propensity for some
high-grade (or less commonly low-grade) endometrial
carcinomas of other types to contain clear cells and
overlap with clear cell carcinoma. In such cases,
deﬁnitive distinction of clear cell carcinoma from
endometrioid carcinoma or serous carcinoma, or a
mixed carcinoma with a clear cell component, may be
challenging; this is compounded by the relative rarity
of endometrial clear cell carcinoma.
Distinction of Clear Cell Carcinoma and Endometrioid
Carcinoma
Since clear cell carcinoma is classiﬁed and
managed as a high-grade carcinoma, it is important
FIG. 6. Immunohistochemistry in clear cell carcinoma. Hepatocyte nuclear factor 1-beta (HNF1B) is frequently expressed in clear cell
carcinoma (A), as is Napsin A (B). A significant minority of endometrial clear cell carcinomas can display aberrant p53 staining (C).
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to distinguish it from low-grade endometrioid
carcinoma, with which it may display morphologic
overlap (82,90). It is not clear whether the prognosis
for patients with clear cell carcinoma differs from
that of patients with grade 3 endometrioid carcino-
ma (or serous carcinoma), with comparably sized
bodies of published literature in support of the
afﬁrmative (6,7,40,69,70,72,81,87,88,97) and of the
negative (10,11,71,73,80,87,91,94,96). Nevertheless,
it is important to distinguish clear cell carcinoma
from other histotypes, because: (a) inaccurate
histotyping may obscure potentially signiﬁcant
differences between histotypes, including stage dis-
tribution, patterns of tumor spread and patterns of
recurrence (11,39,89,93); (b) there is some evidence
that patients with clear cell carcinoma are at
increased risk for venous thromboembolic events
(78,85,95); (c) in some institutions, there is a higher
likelihood that adjuvant therapy would be recom-
mended for a patient with stage I clear cell
carcinoma than for a stage I grade 3 endometrioid
carcinoma (101); (d) strict adherence to diagnostic
criteria by pathologists will aid study of the
molecular proﬁle of clear cell carcinoma (16,102).
Between 12% and 30% of clear cell carcinomas
reportedly contain an endometrioid component
(38–41,83,89,100). The proportion of these tumors
that represent true mixed carcinomas (103) (Fig. 7)
rather than a single histotype displaying phenotypic
diversity (61) is unclear and the wide range in
incidence is likely indicative of interobserver
variability in the classiﬁcation of these tumors (1,4).
It is likely that true mixed endometrioid and clear cell
carcinoma is very uncommon. Areas of morphologic
overlap between clear cell carcinoma and
endometrioid carcinoma are largely attributable to
the presence of clear cells in endometrioid carcinomas,
which may occur for several reasons:
(a) Endometrioid carcinoma with secretory change:
secretory change in endometrioid carcinoma is
characterized by subnuclear and/or supranuclear
vacuoles of glycogen in the epithelial cells of an
otherwise typical endometrioid carcinoma (104,105).
The cells are columnar (38), compared with the
polygonal cells of most clear cell carcinomas. Clear
cell carcinomas generally show at least focal higher
nuclear grade than endometrioid carcinomas with
secretory change (38). These differences are less useful
in high-grade endometrioid carcinoma.
(b) Endometrioid carcinoma with clear cell squamous
differentiation: squamous differentiation in endo-
metrioid carcinoma may have a variety of appear-
ances, including rounded morules, spindled
formations, plaque-like growth, pseudopapillae,
micropapillae, and individual keratinized cells
(106). All these patterns may display prominent
cytoplasmic clearing, usually but not always due to
glycogenation, that can mimic clear cell carcinoma
(107). Avoiding mischaracterization of squamous
differentiation as clear cell carcinoma requires
recognition of the morphologic spectrum of squ-
amous differentiation in endometrioid carcinoma,
the ﬁnding of clear cell areas contiguous with more
typical squamous differentiation or endometrioid
glands, and the absence of cytoarchitectural pat-
terns of clear cell carcinoma.
(c) Endometrioid carcinoma with nonspeciﬁc clear
cell change: some endometrioid carcinomas of
nonsecretory type exhibit nonspeciﬁc clear cell
change within the glandular elements (106).
Features useful in the distinction from clear cell
carcinoma include the absence of the typical
architectural patterns of clear cell carcinoma,
transitions to typical glandular endometrioid
carcinoma and foci of squamous differentiation.
Immunohistochemistry may be of some value in
such cases but there can be signiﬁcant immunophe-
notypic overlap and markers are often not particularly
useful. Negative staining with ER and PR would
favor a diagnosis of clear cell carcinoma but these
markers can be negative in clear cell areas in
endometrioid carcinomas, especially when they ex-
hibit squamous differentiation. While HNF1B and
Napsin A are useful markers of clear cell carcinoma,
FIG. 7. Mixed clear cell and endometrioid carcinoma. Note stark
difference in cell shape, nuclear features and growth patterns.
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they (especially HNF1B) may also be expressed in
clear cells in endometrioid carcinomas.
Distinction of Clear Cell Carcinoma and Serous
Carcinoma, and Mixed Clear Cell/Serous Carcinoma
Although prototypical examples of serous and clear
cell carcinoma are readily distinguished, some cases
present diagnostic problems (1,2,4). This is due to a
number of factors such as the presence of clear cells in
some serous carcinomas and serous-like features in some
clear cell carcinomas. Current clinical management of
patients with serous carcinoma, clear cell carcinoma and
mixed serous carcinoma/clear cell carcinoma is not
substantially different (101). However, this may change
in the future, and accurate diagnosis will facilitate
meaningful study of the clinicopathologic and genomic
proﬁles of each histotype. Immunohistochemical
markers useful in the distinction between serous and
clear cell carcinoma have been discussed previously.
True Mixed Serous-Clear Cell Carcinomas
A mixed endometrial carcinoma is deﬁned in the
latest World Health Organization (WHO) classiﬁca-
tion as a carcinoma composed of 2 or more histologic
subtypes, in which the minor component constitutes
5% or more of the tumor, and in which the 2
components are recognizable on hematoxylin/eosin–
stained sections (103). Each of the components must
be spatially distinct from the other(s), and each must
exhibit morphologic and immunophenotypic features
that, viewed in isolation, is fully diagnostic of one
histotype (61). Since evidence from molecular studies
suggests that there is a high degree of morphologic
mimicry in mixed carcinomas, it is imperative that
each component is morphologically and immunophe-
notypically prototypical (61). As deﬁned, true mixed
serous-clear cell endometrial carcinomas are extreme-
ly uncommon (Fig. 8A).
Serous Carcinomas With Cytoplasmic Clearing
Serous carcinomas that contain cells with clear
cytoplasm are much more likely to represent pure
serous carcinomas than mixed serous-clear cell
carcinomas. The evidence in favor of this interpreta-
tion includes: (1) the frequent presence of “clear cells”
in endometrial carcinomas of various histotypes
minimizes the importance of cytoplasmic clearing as
a stand-alone indicator for clear cell carcinoma. (2)
Data from ovarian carcinomas, in which histotyping
is more reproducible (30–32), indicate that serous
carcinomas with clear cells have a morphologic,
immunophenotypic and molecular proﬁle that is more
consistent with serous carcinoma than clear cell
carcinoma (108–110). (3) One seminal study found
that in serous carcinomas with clear cells, none of the
cases had a tubulocystic pattern, and serous endome-
trial intraepithelial carcinoma was present in a high
proportion of the cases (111).
Clear Cell Carcinoma With Features that Overlap
With Serous Carcinoma (Histologically Ambiguous
Carcinomas)
FIG. 8. Clear cell carcinoma versus serous carcinoma. (A) Mixed serous and clear cell carcinoma. Serous carcinoma with overtly pleomorphic
nuclei, stratification, tumor cell budding and slit-like spaces is found at the top of the image. (B) High-grade endometrial carcinoma displaying
morphologic features overlapping those of clear cell carcinoma and serous carcinoma. The high mitotic index and nuclear pleomorphism are
most characteristic of serous carcinoma.
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These are the most challenging tumors to classify.
The existence of truly ambiguous tumors in the clear
cell carcinoma/serous carcinoma spectrum is one
likely contributing factor to the interobserver varia-
bility that exists in the histotyping of high-grade
endometrial carcinomas (1,2,4). These tumors have
hybrid morphologic features overlapping those of
serous carcinoma and clear cell carcinoma (Fig. 8B).
The frequency of aberrant mutation-type p53 staining
in these cases (36%) (112) is comparable with
that reported in conventional clear cell carcinoma
(33%–38%) (44,47,58,59), and substantially less than
that expected in serous carcinoma. Immunohisto-
chemistry, in our experience, has not proven to be
very useful in the categorization of this group of cases.
The true nature of these cases is unclear, and since
they are not prototypical clear cell carcinoma or
serous carcinoma, we recommend their provisional
categorization in the “ambiguous” category, with
descriptive diagnoses such as “High-grade carcinoma
with clear cell and serous features” until they can be
better categorized by novel modalities in the future.
However, such a diagnosis should be made sparingly and
only in those cases that defy classiﬁcation after thorough
morphologic and immunohistochemical evaluation.
In summary, otherwise typical serous carcinomas
with clear cells should be categorized as serous
carcinomas, and serous carcinomas with spatially
distinct areas of clear cell carcinoma should be
categorized as mixed serous carcinoma-clear cell carci-
nomas. Cases that are not morphologically typical of
either histotype should be reported descriptively (Box 2).
UNDIFFERENTIATED CARCINOMA AND
DEDIFFERENTIATED CARCINOMA
Definition
Undifferentiated carcinoma is a solid-pattern tumor
lacking overt morphologic evidence of epithelial differ-
entiation, except by immunohistochemistry, where focal
(or rarely diffuse) cytokeratin and epithelial membrane
antigen (EMA) expression is usually found. Dediffer-
entiated carcinoma is an undifferentiated carcinoma
found in combination with an endometrioid carcinoma
that is typically low-grade.
The 2003 WHO classiﬁcation deﬁned undifferenti-
ated carcinoma simply as lacking any evidence of
differentiation (113). However, reproducible recogni-
tion of undifferentiated carcinoma was hampered by
the lack of a proper operational deﬁnition until the
2014 WHO classiﬁcation (114), in which undiffer-
entiated carcinoma was described as a monomorphic
neoplasm which may resemble lymphoma, plasmacy-
toma, high-grade endometrial stromal sarcoma or small
cell carcinoma (115). Undifferentiated carcinoma and
dedifferentiated carcinoma of the endometrium should
be considered speciﬁc entities and these diagnoses
should not be used for histologically and/or immuno-
BOX 2. Clear Cell Carcinoma
Summary and recommendations:
 An endometrial carcinoma with clear cells is more likely to be
endometrioid carcinoma or serous carcinoma, rather than
clear cell carcinoma.
 It is recommended that a diagnosis of clear cell carcinoma
should only be made in cases that display prototypical
morphologic features, as observed in prototypical clear cell
carcinoma of the ovary.
 The key morphologic features of clear cell carcinoma include
architectural patterns (papillary, tubulocystic, solid) in
combination with cytologic features [various combinations of
polygonal cells with clear or eosinophilic cytoplasm, hobnail
cells, and attenuated hobnail (ﬂat) cells].
 Clear cell carcinomas lack diffuse nuclear stratiﬁcation and
multilayering, diffuse columnar cell changes and squamous
differentiation.
 A feature that is usually present in clear cell carcinoma is a
relatively low mitotic index compared with the degree of
atypia; however, a high mitotic index does not preclude a
diagnosis of clear cell carcinoma in an otherwise
cytoarchitecurally typical tumor.
 A feature that is usually absent in clear cell carcinoma is
diffuse nuclear pleomorphism; most cases show a variable
degree of cytologic atypia.
 The expected immunophenotype of clear cell carcinoma is
HNF1B-positive, Napsin A-positive, p53-wild-type, and ER-
negative and PR-negative. However, many cases deviate from
this immunoproﬁle.
 A mixed serous carcinoma-clear cell carcinoma should have
morphologically recognizable, clearly distinct areas of clear
cell carcinoma and serous carcinoma. Each component,
should display a set of morphologic and immunophenotypic
attributes that is diagnostic of one histotype and the minor
component should constitute at least 5% of the tumor. As
most tumors diagnosed as mixed endometrial carcinoma in
the past show a uniform genotype, it is likely that most
carcinomas with serous and clear cell features will prove to be
serous carcinoma and that true mixed clear cell-serous
carcinomas are very uncommon.
 Otherwise typical serous carcinoma with clear cells should be
categorized as serous carcinoma. The clear cell areas retain
the expected immunophenotype of serous carcinoma, and
their morphologic features, viewed in isolation, would not be
diagnostic of clear cell carcinoma.
 Cases that are histotypically ambiguous and have both serous
carcinoma and clear cell carcinoma-like morphologic features,
but lack a proﬁle that would allow their deﬁnitive
classiﬁcation into 1 group, should be reported descriptively.
 As aberrant mutation-type p53 staining is seen in almost all
serous carcinomas, but also in smaller proportions of clear cell
carcinomas and grade 3 endometrioid carcinomas, p53
immunohistochemistry is useful predominantly for its high
negative predictive value for serous carcinoma (i.e. tumors
with wild-type p53 staining are highly unlikely to be serous
carcinoma).
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phenotypically ambiguous high-grade tumors that are
difﬁcult to classify (116).
Undifferentiated and dedifferentiated carcinomas are
clinically aggressive malignancies that are probably
under-recognized (115,117,118). They have been widely
recognized only in the past decade, and data pertaining
to them is based upon a limited number of relatively
small studies (115,117–126). In our experience, undif-
ferentiated carcinomas and dedifferentiated carcinomas
together represent ∼10% of high-grade endometrial
carcinomas and hence about 2% of endometrial
carcinomas overall (127). Silva et al. (124) reported
that undifferentiated carcinomas accounted for 9% of
all endometrial carcinomas; however, this report was
from a major tertiary cancer center and it is unclear
whether the frequency was inﬂated due to inclusion of
referral and consultation cases.
Key Morphologic Features
Undifferentiated carcinoma is a monomorphic neo-
plasm composed of small to intermediate-sized cells
arranged in sheets without any obvious glandular
differentiation. They frequently exhibit a characteristi-
cally “dyscohesive” pattern and the low-power appear-
ance raises a differential diagnosis of lymphoma,
plasmacytoma, high-grade endometrial stromal sarco-
ma or small cell carcinoma (Fig. 9A) (115,118,121,124).
Approximately 40% of undifferentiated carcinomas
are associated with a component of FIGO grade 1 or 2
endometrioid carcinoma; these cases are termed “de-
differentiated carcinoma” (Fig. 9B). It is possible that in
some cases of undifferentiated carcinoma, an
antecedent low-grade component was overgrown by
the undifferentiated element. When present, the
differentiated low-grade endometrioid component is
typically found lining the endometrial cavity, with the
undifferentiated component present deep to it. This
may account for a diagnosis of low-grade endometrioid
carcinoma in a biopsy specimen and dedifferentiated
carcinoma at hysterectomy. In rare cases, low-grade
endometrioid carcinoma is present in the uterus and the
undifferentiated component is only seen in the
metastases, which may be identiﬁed synchronously or
subsequently (117,118,121,124). Rare cases contain foci
of FIGO grade 3 endometrioid carcinoma juxtaposed
with undifferentiated carcinoma (118).
Additional morphologic features that are present in
some undifferentiated and dedifferentiated carcinomas
include focal alveolar, nested and vaguely corded
or trabecular growth patterns, rhabdoid/plasmacytoid
morphology (vesicular nucleus containing a large
nucleolus and abundant pink cytoplasm; Fig. 9C),
focal marked nuclear pleomorphism (Fig. 9D),
multinucleation, spindling, and “abrupt” keratinization
(118,124,128,129). Some tumors also show prominent
tumor-inﬁltrating lymphocytes and myxoid stroma.
The morphologic criteria have continued to evolve and
vary to some extent between studies. For example, the
degree of permissible neuroendocrine differentiation
(as judged immunohistochemically) was initially
restricted to <10% of tumor cells (115), but in one
subsequent study of undifferentiated carcinoma, “diffuse
staining” was recorded in 9% of cases; we recommend
that neuroendocrine marker positivity in undifferentiated
carcinoma should be limited to <10% of the tumor
cells (129).
Immunohistochemical Features and Genotype
The majority of undifferentiated carcinomas (and
the undifferentiated component of dedifferentiated
carcinoma) lack expression of PAX8, ER, and PR but
up to 20% of tumors may show focal staining with
these markers (121,130). P53 expression is usually
wild-type but is aberrant (mutation-type) in a
minority of cases. More than 80% of undifferentiated
carcinomas display evidence of epithelial differentia-
tion in the form of intense EMA and cytokeratin
(especially cytokeratin 18) staining of a small pro-
portion of tumor cells (Fig. 10A); diffuse expression of
EMA and cytokeratins is not typically found but can
occur. Tumor cells typically express vimentin and a
substantial number express CD138. E-cadherin
labeling is absent or minimal (121,130–132). CD34
expression, which is otherwise very uncommon in
epithelial neoplasms, is sometimes seen (133).
Chromogranin and/or synaptophysin staining can be
present, but only in a minority of tumor cells (o10%)
(130). Loss of BRG-1 (the protein product of
SMARCA4) expression can be seen (Fig. 10B),
particularly in examples that have DNA MMR
protein deﬁciency and some cases show loss of INI-1
(the protein product of SMARCB1) or ARID1A
(125,134). BRG-1, INI-1, and ARID1A are involved
in chromatin remodeling through SWI/SNF
complexes (125,134). Loss of expression of MLH1
and PMS2, mostly due to hMLH1 promoter
methylation is seen in ∼50% to 60% of cases. Rare
cases with germline DNA MMR gene mutations
diagnostic of Lynch syndrome have been reported
(135). Occasional cases may also harbor a hotspot
POLE mutation affecting the exonuclease domain.
Possible mechanisms underlying the transition from
differentiated to undifferentiated carcinoma include
S53HIGH-GRADE ENDOMETRIAL CARCINOMAS
Int J Gynecol Pathol Vol. 38, No. 1 Supplement 1, January 2019
FIG. 9. Undifferentiated and dedifferentiated carcinoma. (A) Prototypical undifferentiated carcinoma. (B) Dedifferentiated carcinoma. (C)
Undifferentiated carcinoma containing rhabdoid cells in a myxoid matrix. (D) Undifferentiated carcinoma containing monomorphic and
pleomorphic cells. (E) Undifferentiated carcinoma containing multinucleate giant cells. This pattern corresponds to the “giant cell carcinoma”
of Scully and is unrelated to other types of undifferentiated carcinomas discussed herein.
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the acquisition of mutations in SMARCA4, ARID1B,
CTNNB1, PPP2R1A or TP53 (136).
Differential Diagnosis
Accurate diagnosis is important in view of the poor
prognosis of undifferentiated/dedifferentiated carcino-
ma, and this is likely to become even more important as
tumor subtype-speciﬁc targeted therapies are developed.
The differential diagnosis of undifferentiated carci-
noma includes grade 3 endometrioid carcinoma, serous
carcinoma with a solid architecture, lymphoma, plas-
macytoma, melanoma, high-grade endometrial stromal
sarcoma, high-grade neuroendocrine carcinoma (small
cell and large cell neuroendocrine carcinoma), various
metastatic carcinomas, rhabdomyosarcoma, undiffer-
entiated sarcoma and other sarcomas, all of which can
be identiﬁed with careful morphologic evaluation and
the prudent use of immunohistochemical stains. As well
as these neoplasms, dedifferentiated carcinoma may be
confused with grade 2 endometrioid carcinoma and
carcinosarcoma.
Many pleomorphic epithelial tumors were likely
diagnosed as “undifferentiated carcinoma” before the
recognition of the monomorphic tumors currently
categorized as undifferentiated carcinomas. Anecdo-
tal experience suggests that many, if not most,
pleomorphic carcinomas are merely an extreme end
of the spectrum of high-grade endometrial carcino-
mas, such as serous carcinomas. As with other
pleomorphic tumors, the differential diagnosis with
melanoma, sarcoma, and hematolymphoid tumors
may need to be explored and immunohistochemistry
will assist in this distinction.
In contrast to grade 3 endometrioid carcinomas,
undifferentiated carcinomas are dyscohesive and do
not exhibit epithelial formations, such as glands,
although occasional nests and trabeculae are allowed.
Undifferentiated carcinoma forms diffuse monoto-
nous sheets, sometimes in a myxoid stroma. Most
grade 3 endometrioid carcinomas, on the other hand,
are composed of cohesive cells with at least focal
glandular formation and squamous differentiation,
which may be abortive. While gland formation
excludes a diagnosis of undifferentiated carcinoma,
the distinction of “true” glands from lacunar-type
spaces occurring secondary to apoptosis/necrosis or
artifact can be problematic and subjective. The
distinction between undifferentiated carcinoma and
grade 3 endometrioid carcinoma may be particularly
problematic in poorly ﬁxed specimens and sometimes
cannot be resolved, even with immunohistochemistry;
such cases are probably best diagnosed as “high-grade
endometrial carcinoma” with an explanatory note.
Dedifferentiated carcinomas with a signiﬁcant low-
grade glandular component may be misclassiﬁed as
grade 2 endometrioid carcinoma, signiﬁcantly under-
estimating their aggressive behavior (116,124). Dedif-
ferentiated carcinomas may also be confused with
grade 3 endometrioid carcinomas but the former is a
more overtly “biphasic” neoplasm in view of its
distinct low-grade endometrioid and undifferentiated
components. However, extensive sampling may be
required to identify the differentiated component of
dedifferentiated carcinoma. Although by deﬁnition
FIG. 10. Immunohistochemistry in undifferentiated carcinoma of monomorphic type. (A) Focally intense labeling with CK18 in the absence of
PAX 8 expression (latter not shown). (B) Loss of BRG-1 (SMARCA4) expression.
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grade 3 endometrioid carcinoma shows a predom-
inant solid growth pattern, up to 49% of the tumor
can show glandular differentiation and there is often
an intimate admixture of the solid and glandular
components within the same nests. The cells within
the solid areas and those forming glands usually have
similar cytologic appearances. In contrast, the glan-
dular and diffuse elements in dedifferentiated carci-
noma are typically separate, and the diffuse
component shows greater cytologic atypia than the
low-grade glandular component. A solid cohesive
growth pattern is characteristic of grade 3 endome-
trioid carcinomas whereas cellular dyscohesion and
rhabdoid morphology are more characteristic of the
undifferentiated component of dedifferentiated carci-
noma. The distinction between dedifferentiated carci-
noma and carcinosarcoma is discussed in the section
on carcinosarcoma.
Immunohistochemically, undifferentiated carcinomas
and the undifferentiated component of dedifferentiated
carcinomas often show loss of PAX8, E-cadherin, ER,
and PR immunoreactivity (121,130). In contrast, grade
3 endometrioid carcinomas usually retain PAX8
expression while hormone receptor expression is
variable (8). Loss of BRG1 and/or INI1 expression
has been reported in undifferentiated carcinoma and the
undifferentiated component of dedifferentiated carcino-
mas (125,134); loss of another subunit of the SWI/SNF
complex, BAF250a (the protein product of ARID1A) is
common in both low-grade and high-grade endometrial
carcinomas (137,138). Overall, therefore a cytokeratin/
EMA-focal and PAX8/ER/E-cadherin-negative immu-
noproﬁle, along with loss of BRG-1 or INI-1 expression
would favor undifferentiated or dedifferentiated carci-
noma over grade 3 endometrioid carcinoma (Box 3).
CARCINOSARCOMA
Definition
Carcinosarcoma (formerly termed “malignant mixed
Müllerian tumor”) is a biphasic endometrial carcinoma
composed of a component of high-grade sarcoma (with
or without heterologous elements) juxtaposed with a
high-grade carcinoma of the following types: high-
grade endometrioid carcinoma, serous carcinoma, clear
cell carcinoma, undifferentiated carcinoma, or a
histologically ambiguous, high-grade adenocarcinoma.
The mesenchymal (sarcomatous) component is pre-
sumed to derive from the epithelial component (or
concurrent with it from the same progenitor cell) via
shifts in differentiation.
Key Morphologic Features
By deﬁnition, carcinosarcoma consists of a high-
grade carcinomatous component admixed with ma-
lignant mesenchymal elements. There is often a
sharp demarcation between the carcinomatous and
sarcomatous elements. While immunohistochemistry
generally plays a limited role in diagnosis, broad-
spectrum cytokeratins may be helpful in problematic
cases, by distinguishing between poorly differentiated
carcinomatous and sarcomatous elements. Speciﬁc
skeletal muscle markers (especially myogenin) may be
useful in conﬁrming heterologous rhabdomyoblastic
differentiation.
The presence of even minimal amounts of carci-
nomatous epithelium has traditionally been used to
BOX 3. Undifferentiated and Dedifferentiated
Carcinoma
Summary and recommendations:
 Undifferentiated endometrial carcinoma can be diagnosed
when morphologic features of epithelial differentiation are
absent.
 Entities in the differential diagnosis should be always be
excluded.
 Ideally these carcinomas should be tested for DNA MMR
proteins, BRG-1 and INI-1 using immunohistochemistry as a
screen. This allows triage for Lynch syndrome and
determination of eligibility for clinical trials focused on host
immunity and chromatin remodeling.
 The morphologic criteria for undifferentiated carcinoma and
dedifferentiated carcinoma continue to evolve, inevitably
leading to some variability and subjectivity in diagnosis. In
the interim, it may be useful for pathologists to distinguish
those cases with classic/prototypical appearances (diffuse/
patternless architecture, monomorphic cytology, dyscohesive
appearance, typical immunoproﬁle), from those cases
demonstrating variant features.
 Immunohistochemical studies are essential before making a
diagnosis of undifferentiated carcinoma or dedifferentiated
carcinoma, particularly to exclude potential histologic
mimics. The latter may include nonepithelial neoplasms
(lymphoma, plasmacytoma, melanoma, sarcoma), metastatic
malignancies, and other high-grade endometrial carcinomas
such as neuroendocrine carcinomas.
 It is recommended that immunohistochemical expression of
neuroendocrine markers in undifferentiated carcinoma be
restricted to <10% of tumor cells.
 When the differential diagnosis is with grade 3 endometrioid
carcinoma, loss of PAX8 and E-cadherin expression and only
focal cytokeratin and EMA staining can be useful in
supporting a diagnosis of undifferentiated carcinoma or
dedifferentiated carcinoma.
Unresolved issues:
 The optimal immunohistochemical panel for distinguishing
FIGO grade 3 endometrioid carcinoma and undifferentiated
carcinoma is uncertain, but it is likely to include PAX8, pan-
cytokeratin, EMA, and E-cadherin.
 The role of molecular analysis in diagnosis at this point is
uncertain.
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qualify a predominantly sarcomatous tumor as a
carcinosarcoma (139). The literature is inconsistent on
the volume of sarcomatous differentiation required to
label a tumor as a carcinosarcoma, which has ranged
from as little as 2% (140) to 25% (141). The authors
recommend that the sarcomatous component should
measure at least 1 mm in one dimension; while this is
an arbitrary ﬁgure that is not evidence-based, it
reﬂects the authors’ view that a minimal sarcomatous
component should not result in a diagnosis of
carcinosarcoma. The clinical signiﬁcance, if any, of
minimal volume sarcoma in a predominantly carci-
nomatous tumor has not been systematically studied.
In contrast, high volume sarcomatous differentiation
may portend more aggressive behavior and poor
prognosis (139,140,142–144). Some studies also sug-
gest that such largely sarcomatous tumors tend to be
associated with pure sarcomatous metastases, which
spread preferentially via lymphohematogenous routes
to lymph nodes and distant sites, without peritoneal
spread (139,140,142,143). This is in contrast to most
carcinosarcomas in which the epithelial component
preferentially metastasizes to peritoneal sites.
Carcinosarcomas are divided into homologous and
heterologous types, according to whether the mesen-
chymal component exhibits differentiation that is
intrinsic (endometrial stromal sarcoma or leiomyo-
sarcoma; Figs. 11A, B) or extrinsic (chondrosarcoma,
Fig. 11C; rhabdomyosarcoma, Fig. 11D; etc.) to the
uterus. Accurate subclassiﬁcation of the sarcomatous
component is a useful exercise but is not currently
relevant to management. This separation was based
on reports suggesting a more ominous prognosis for
heterologous tumors (145,146) but this remains
controversial. One follow-up study concluded that
the prognosis for both homologous and heterologous
FIG. 11. Carcinosarcoma. (A and B) Examples of homologous carcinosarcoma. (C and D) Examples of carcinosarcoma with heterologous
elements, with cartilaginous differentiation (C) and rhabdomyoblastic differentiation (D).
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carcinosarcomas was equally poor (139). However, a
more recent report found signiﬁcantly poorer 3-yr
survival in patients with stage I heterologous tumors
(45%) than in those with homologous tumors (93%)
(147). The authors concluded that heterologous
carcinosarcomas exhibited true sarcomatous
differentiation and that homologous tumors were
best classiﬁed as metaplastic carcinomas based on
their behavioral similarity to high-grade endometrial
carcinomas.
The morphology of metastases from carcinosarcomas
is variable but the majority contain an epithelial
component. One study (142) evaluated the cellular
composition of 62 metastases, 51 of which were
diagnosed at the time of surgery. Carcinoma or
carcinosarcoma accounted for over 90% of metastatic
tumors, with only a few comprising pure sarcoma. The
characteristics of the stromal component, including
grade, mitotic index, and the presence and types of
heterologous elements, has not been associated with
outcome in most studies. In contrast, an epithelial
component consisting of serous carcinoma correlates
with a higher frequency of metastases. Features
associated with poor outcome in carcinomas, such as
deep myometrial invasion, lymphovascular space in-
vasion, and cervical involvement, are also associated
with adverse prognosis in carcinosarcomas (139,142).
A recent large-scale molecular genetic analysis of
uterine carcinosarcomas by the Cancer Genome Atlas
(148) revealed extensive copy-number alterations and
highly recurrent somatic mutations, most frequently
in TP53, PTEN, PIK3CA, PPP2R1A, FBXW7, and
KRAS. The similarity in mutational proﬁle to uterine
endometrioid and serous carcinomas provides ge-
nomic support for the categorization of carcinosarco-
mas as a subset of uterine carcinomas. A proportion
of carcinosarcomas was also characterized by an
epithelial-to-mesenchymal transition (EMT) gene
signature (148).
In practice, tumors with malignant epithelial and
mesenchymal differentiation are reported as carcino-
sarcomas, with additional comments clarifying the cell
type and grade of the epithelial component (although
typing of the epithelial component may be particularly
difﬁcult in carcinosarcomas), and other parameters that
are associated with prognosis in epithelial tumors. The
presence of heterologous elements and their differ-
entiation should also be noted.
Differential Diagnosis of Carcinosarcoma
A number of neoplasms may enter into the differ-
ential diagnosis of carcinosarcoma (Box 4).
Dedifferentiated carcinomas and carcinosarcomas
show a low-power biphasic appearance but in the case
of carcinosarcoma, the more diffuse tumor compo-
nent comprises cytologically malignant mesenchymal
elements that are typically spindled and pleomorphic
and may exhibit heterologous differentiation (149).
This contrasts with the monotonous round cells of the
undifferentiated component of most dedifferentiated
carcinomas. While dedifferentiated carcinoma can
rarely contain a population of somewhat spindled
cells, this is usually a minor feature in contrast to the
more overtly sarcomatous appearances of carcinosar-
coma. Many carcinosarcomas exhibit heterologous
BOX 4. Carcinosarcoma
Summary and recommendations:
 The diagnosis of carcinosarcoma requires the presence of
sufﬁcient amounts of both carcinomatous and sarcomatous
components visible on routinely stained sections to verify a
biphasic tumor.
 Epithelial component.
J The entire spectrum of high-grade epithelial differentiation
may be seen in these tumors. However, some patterns
appear more strongly associated with carcinosarcoma.
These include solid components with marked
pleomorphism and variable differentiation, bizarre
squamous differentiation and more primitive or
“embryonal” glandular growth patterns.
 Mesenchymal (sarcomatous) component.
J Should be conﬁdently classiﬁable as sarcoma either
histologically or with supportive immunohistochemical
stains.
J Should measure at a minimum 1mm in one dimension; this
is an arbitrary ﬁgure, but reﬂects the authors’ view that a
minimal sarcomatous component should not result in a
diagnosis of carcinosarcoma.
J Heterologous mesenchymal differentiation patterns may be
seen with pure heterologous sarcomas but are much more
likely to signify the presence of a carcinosarcoma.
 Exclude morphologic mimics of carcinosarcoma before
making the diagnosis.
J Dedifferentiated carcinoma.
J Adenocarcinoma with prominent desmoplasia (this is
excluded by the blandness of the stromal reaction and the
lack of nuclear atypia).
J Solid carcinomas or carcinomas with a spindle cell
architecture.
J Corded and hyalinized endometrioid carcinoma.
J Carcinomas with benign mesenchymal elements, for
example, metaplastic bone.
J Biphasic carcinomas.
J Endometrial stromal neoplasm with sex-cord–like
differentiation.
J Adenosarcoma.
Unresolved questions:
 What is the minimal amount of carcinomatous epithelium
required to designate a predominantly sarcomatous tumor as
carcinosarcoma?
 What is the signiﬁcance of the type and grade of glandular
differentiation?
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mesenchymal differentiation, most commonly in the
form of chondrosarcoma, rhadomyosarcoma or
osteosarcoma, but this is not a feature of dediffer-
entiated carcinoma. The epithelial elements of these
tumors also differ in that the glandular component of
dedifferentiated carcinoma is most often a low-grade
endometrioid carcinoma, whereas in most carcinosar-
comas, the epithelial element is a high-grade carcinoma
(serous, clear cell, grade 3 endometrioid carcinoma or
difﬁcult-to-classify high-grade adenocarcinoma). How-
ever, the carcinomatous component of a carcinosarco-
ma can have undifferentiated appearances, at least in
some areas, and the distinction from undifferentiated
carcinoma or dedifferentiated carcinoma may be very
difﬁcult, particularly in biopsy specimens.
Immunohistochemistry has limited utility in this
differential diagnosis. Typically, cytokeratins are
diffusely expressed by the epithelial component of
carcinosarcomas and there is sometimes focal staining
of the mesenchymal elements (150). The latter may
also express more speciﬁc mesenchymal markers if
heterologous differentiation is present (eg, myogenin
in rhabdomyosarcoma). Vimentin and p16 staining
are of limited value since many dedifferentiated
carcinomas are positive (130,132). Similarly, PAX8
is not useful in this differential diagnosis since the
mesenchymal component of carcinosarcoma, like the
undifferentiated component of dedifferentiated carci-
noma, is usually PAX8-negative (151). As noted
above, loss of MMR protein expression is relatively
common (∼50%–60% of cases) in dedifferentiated
carcinoma (118,125,130), and some tumors arise in
patients with Lynch syndrome (152). In contrast,
abnormal MMR protein expression is much less
common in carcinosarcoma; the Cancer Genome
Atlas analysis found microsatellite instability in 2 of
57 (4%) cases (148), although other studies have
reported frequencies of MMR-deﬁcient cases ranging
between 6% and 33% (153,154).
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